OncoMatch/Clinical Trials/NCT06350825
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Is NCT06350825 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies ADT+second-generation antiandrogens ± chemotherapy for metastatic prostate cancer.
Treatment: ADT+second-generation antiandrogens ± chemotherapy — To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Clinical stage M1a (distant lymph node positive), M1b (bone metastasis), or M1c (visceral organ metastasis)
Demographics
Prior therapy
Cannot have received: local treatment (prostate radiotherapy, cryotherapy)
Prostate cancer has not received local treatment (e.g., prostate radiotherapy, cryotherapy, etc.); History of prior local treatment for prostate cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06350825 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior local treatment disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages